These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31009858)

  • 1. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.
    Sopa N; Larsen EC; Westring Hvidman H; Andersen AN
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():42-47. PubMed ID: 31009858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose HP-hMG in an antagonist protocol for IVF in ovulatory and anovulatory patients with high AMH.
    Sopa N; Larsen EC; Nyboe Andersen A
    Gynecol Endocrinol; 2018 Jul; 34(7):623-626. PubMed ID: 29345163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
    Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
    Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone.
    Nielsen AP; Korsholm AS; Lemmen JG; Sylvest R; Sopa N; Nyboe Andersen A
    Gynecol Endocrinol; 2016 Aug; 32(8):625-628. PubMed ID: 26891977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
    Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome.
    Yovich JL; Alsbjerg B; Conceicao JL; Hinchliffe PM; Keane KN
    Drug Des Devel Ther; 2016; 10():2561-73. PubMed ID: 27563236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF.
    Friis Petersen J; Løkkegaard E; Andersen LF; Torp K; Egeberg A; Hedegaard L; Nysom D; Nyboe Andersen A
    Hum Reprod Open; 2019; 2019(1):hoz003. PubMed ID: 30895268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
    Andersen AN; Witjes H; Gordon K; Mannaerts B;
    Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.